

Bone Therapeutics extends Kasios collaboration

Extension of collaboration to develop ready-to-use solutions to simplify spinal fusion procedures and reduce intervention time

Gosselies, Belgium, 2 February 2016 - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces the extension of its collaboration with Kasios, a synthetic bone substitute specialist, to develop next generation spinal fusion integrated products.

Under the new collaboration, the companies aim to combine Bone Therapeutics' ALLOB[®] cells with Kasios' spinal fusion cage containing a 3D-bioprinted synthetic matrix (or 'waffle'). The goal of this combined product is to simplify the surgical procedure and accelerate the fusion process.

Spinal fusion is considered to be the gold standard for treating a broad spectrum of degenerative spine disorders, including degenerative disc disease, to relieve pain and improve function. Spinal fusion consists of bridging two or more vertebrae with the use of a cage and graft material, traditionally an autologous or synthetic bone graft, for fusing an unstable portion of the spine or immobilizing a painful vertebral motion segment. Although this procedure is routine, failure to achieve fusion between the vertebrae is quite common. Bone Therapeutics aims to accelerate the fusion process and increase success rates of the surgery using its allogeneic bone cell therapy product, ALLOB[®].

Kasios specializes in the development of spinal fusion cages and synthetic bone substitutes. In a previous collaboration, the companies successfully combined Kasios' synthetic micro-granules with ALLOB[®] cells in preclinical studies, showing that the combination resulted in increased bone formation. In a first step, the biocompatibility of the matrix with ALLOB[®] will be tested in preclinical studies.

The companies ultimately aim to provide an integrated ready-to-use product for surgeons that simplifies the procedure and reduces operation time.

Enrico Bastianelli, CEO of Bone Therapeutics, comments: *"We are delighted to extend our collaboration with Kasios, following encouraging results from the work we have completed so far. We believe that combining our products offers potential for an exciting and more convenient alternative for surgeons in spinal fusion procedures and we look forward to continuing to work together."*

Nicolas Guéna, CEO of Kasios, adds: *"By combining our products, we aim on the one hand to increase bone regeneration efficacy and on the other hand to bring a solution to surgeons that is easier and faster to use."*

-Ends-

About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products intended for bone fracture repair and fracture prevention. The current standard-of-care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.

PREOB[®], Bone Therapeutics' autologous bone cell product, is currently in pivotal Phase IIB/III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for severe osteoporosis. ALLOB[®], its allogeneic "off-the-shelf" bone cell product, is in Phase I/IIA for the treatment of delayed-union fractures and lumbar fusion for degenerative disease of the spine. The Company also runs preclinical research programs and develops novel product candidates.

Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics' regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 11 patent families. Further information is available at www.bonetherapeutics.com.



About Kasios

Founded in 2001, Kasios is a French company based in Gilly (Belgium) and L'Union (France).

Kasios specializes in the research, development, production and sale of calcium phosphate based synthetic bone substitutes. Today, the company's bone substitutes are marketed in over fifty countries worldwide.

Several years ago, Kasios developed a unique 3D printing technique for the manufacture of bone substitutes. This technique, unrivalled anywhere in the world, is used to produce complex porous implants to fill cervical and lumbar cages.

Kasios then developed a full range of cages pre-filled with a bone substitute and pre-loaded on a disposable cage inserter. The assembly is supplied sterile in a double-blister pack.

For more information, please contact:

Bone Therapeutics SA

Tel: +32 (0)2 529 59 90

Enrico Bastianelli, Chief Executive Officer/ Wim Goemaere, Chief Financial Officer

investorrelations@bonetherapeutics.com

For Belgium and International Media Enquiries

Consilium Strategic Communications

Tel: +44 (0) 20 3709 5701

Amber Fennell, Jessica Hodgson and Hendrik Thys

bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries

NewCap Investor Relations & Financial Communications

Tel: + 33 (0)2 44 71 94 94

Pierre Laurent and Nicolas Merigeau

bone@newcap.fr

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.